Aethlon Medical, Inc. (NASDAQ: AEMD) is leveraging its technology to help combat the spread of Zika virus, which is causing pregnant women to give birth to babies with unusually small head and underdeveloped brain.
In its latest update on Zika-themed research, Aethlon Medical, Inc. (NASDAQ: AEMD) has said that its Aethlon Hemopurifier showed remarkable promise in rapid capture of Zika virus in human blood.
In cell culture fluid, the company said that Hemopurifier was able to achieve 95% clearance of Zika virus in 5.5 hours. But in human blood, the success rate in clearance of Zika was about 50% in 5 hours. The company said that it only used small versions of Hemopurifier in the Zika studies.
Tackling viral pathogen infections
Aethlon’s Hemopurifier is being leveraged as a countermeasure in combating viral pathogens that are either untreatable with existing drug therapies or have developed resistance to those treatments.
In the case of Zika virus, Hemopurifier’s rapid capture of the virus suggests that Aethlon’s technology could become a key frontline defense against the disease. There is massive revenue opportunity in Zika treatment given the threat that the disease is posing to the world.
Troublesome Zika strain
According to Aethlon Medical, Inc. (NASDAQ: AEMD), its Zika study was conducted using a strain of the virus that has recently spread to Puerto Rico from South America and is likely behind the infections in the U.S.
Data from the CDC show that more than 7,300 people in the U.S. have been diagnosed with Zika virus. Zika infection has become so serious that the World Health Organization (WHO) has declared the virus a global health concern.
Besides creating deformities in newborns, the virus also leads to a condition called Guillain-Barre syndrome, which can cause paralysis.
Following the milestone attained with Zika study, Aethlon Medical, Inc. (NASDAQ: AEMD) is focused on targeting its Hemopurifier on other troublesome infectious viral pathogens. One of those is the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), whose mortality rate is currently cited at 30%. AEMD is working with the Defense Advanced Research Projects Agency (DARPA) to leverage Hemopurifier in the capture of MERS-CoV.
What transpired in F1Q2017 for Aethlon Medical, Inc. (NASDAQ: AEMD)?
Aethlon Medical, Inc. (NASDAQ: AEMD) logged EPS loss of $0.28 in its F1Q2017 ended June 30. The loss widened from $0.18 in the comparable quarter last year. But the company’s consolidated expenses dipped from $1.3 million in the prior-year quarter to $1.1 million in the latest quarter.